Pharming Group N.V.
PHARDrugs in Pipeline
6
Phase 3 Programs
4
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How PHAR's past catalysts played out
Leniolisib
PIDs Linked to PI3K
i.v. recombinant human C1 inhibitor
Genetic Disorders
recombinant human C1 inhibitor
Hereditary Angioedema
rhC1INH
Hereditary Angioedema
Ruconest
Confirmed Coronavirus Disease
KL1333
Primary Mitochondrial Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Leniolisib | Phase 3 | PIDs Linked to PI3K | - | - |
i.v. recombinant human C1 inhibitor | Phase 3 | Genetic Disorders | - | - |
recombinant human C1 inhibitor | Phase 3 | Hereditary Angioedema | - | - |
rhC1INH | Phase 3 | Hereditary Angioedema | - | - |
Ruconest | Phase 2 | Confirmed Coronavirus Disease | - | - |
KL1333 | Phase 2 | Primary Mitochondrial Disease | - | - |
Frequently asked questions
What is in Pharming Group N.V.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Pharming Group N.V.'s (PHAR) pipeline across Phase 3, Phase 2. Its lead program is Leniolisib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Pharming Group N.V.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Pharming Group N.V. (PHAR) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track PHAR biotech catalysts?→
Add PHAR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Pharming Group N.V.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.